0      0

AONN+ Annual 2020

FRI05 - Product Theater 2 | A CDK 4 & 6 Inhibitor with Overall Survival Data for Women With HR+, HER2- Metastatic Breast Cancer, Including Those Likely to Do Worse (non-CE) Presentation by Lilly Oncology

Nov 6, 2020 10:30am ‐ Nov 6, 2020 11:30am


Join us to learn more about a CDK 4 & 6 inhibitor with overall survival data for women with HR+, HER2- metastatic breast cancer, including those likely to do worse.


  • Blanca Ledezma, MSN, NP, Nurse Practitioner, UCLA Santa Monica Hematology/Oncology

You must be logged in and own this session in order to post comments.